Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

linigliptin

- PMLiVE

Lilly’s gastric cancer prospect clears phase III trial

Ramucirumab improved both overall and progress-free survival

- PMLiVE

NICE stroke guidance boost for Boehringer’s Actilyse

Institute changes guidance on alteplase use

- PMLiVE

Lilly, Roche drugs selected for Alzheimer’s prevention study

Large-scale study will involve Roche's gantenerumab and Lilly's solanezumab

- PMLiVE

Independent analysis raises hope for Lilly’s Alzheimer’s drug

Pooled results show solanezumab slowed cognitive decline in subgroup by 34 per cent

- PMLiVE

NICE in U-turn on Novartis’ Lucentis in diabetic macular oedema

Patient access scheme influences draft recommendation

- PMLiVE

Merck & Co says Januvia follow-up looking good

Diabetes drug shows promise in phase II as once-weekly treatment

JDRF and Lilly take diabetes education to secondary schools

The partnership will use a new resource to teach students about type 1 diabetes

EMA recommends Lilly’s erectile dysfunction drug for enlarged prostate

Cialis would be first drug available in Europe for both ED and BPH

Novo Nordisk invests $100m in research in China

Expands existing site in Beijing

Novartis building

CHMP backs trio of Novartis products

Including two diabetes drugs and one for non-cancerous kidney tumours

FDA launches safety probe into Boehringer’s Mirapex

Regulator concerned about potential heart risk link to Parkinson's disease drug

Diabetes apps present usability problems for older adults

Researchers find a range of potential design problems with smartphone apps

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links